PEAR-TNBC recruits first patient
29th of June 2022
We are delighted to announce that we have recruited our first breast cancer patient to the PEAR-TNBC trial. The patient underwent a biopsy last week at St. Bartholomew’s NHS Trust, and we have been busy culturing and treating the breast cancer cells in the lab.
//
The Pear Bio Platform allows us to grow and treat multiple microtumors in parallel so that we can determine which drugs are likely to be effective. Unlike other tests that measure a biomarker, we directly test different drugs in parallel on an individual patient tumor sample.
//
PEAR-TNBC is a multi-centre, observational study for patients with newly diagnosed Triple Negative Breast Cancer who are about to start chemotherapy as their first treatment (“neoadjuvant chemotherapy”). Patients receive standard treatment, and we treat the tumor samples in the lab with the same chemotherapy as the treating team has chosen to use. The primary endpoint of the trial is to see how accurately the patient responses to treatment can be predicted by the Pear Bio test.
//
PEAR-TNBC is currently open at St. Bartholomew’s, and will open in other centers across the UK in 2022 to recruit 30 patients with TNBC. We have a range of trials for other cancer types under active development.
//
See what we have in the works
